CFA III - Checkpoint Therapeutics CEO President
| CKPT Stock | USD 4.10 0.07 1.74% |
CEO
CFA III is CEO President of Checkpoint Therapeutics
| Age | 48 |
| Address | 95 Sawyer Road, Waltham, MA, United States, 02453 |
| Phone | 781 652 4500 |
| Web | https://checkpointtx.com |
Checkpoint Therapeutics Management Efficiency
The company has return on total asset (ROA) of (3.167) % which means that it has lost $3.167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.2038) %, meaning that it created substantial loss on money invested by shareholders. Checkpoint Therapeutics' management efficiency ratios could be used to measure how well Checkpoint Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Checkpoint Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 4.17 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (9.16). Change To Liabilities is likely to gain to about 22.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2024.Similar Executives
| Found 4 records | CEO Age | ||
| Manuel MD | Mustang Bio | 70 | |
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Jason Okazaki | Assembly Biosciences | 48 | |
| MSc JD | Cue Biopharma | 63 | |
Management Performance
| Return On Equity | -12.2 | ||||
| Return On Asset | -3.17 |
Checkpoint Therapeutics Management Team
Elected by the shareholders, the Checkpoint Therapeutics' board of directors comprises two types of representatives: Checkpoint Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Checkpoint. The board's role is to monitor Checkpoint Therapeutics' management team and ensure that shareholders' interests are well served. Checkpoint Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Checkpoint Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Gray, Corporate CFO | ||
| III CFA, CEO Pres | ||
| CFA III, CEO President |
Checkpoint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Checkpoint Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.2 | ||||
| Return On Asset | -3.17 | ||||
| Operating Margin | (162.76) % | ||||
| Current Valuation | 195.51 M | ||||
| Shares Outstanding | 48.13 M | ||||
| Shares Owned By Insiders | 15.51 % | ||||
| Shares Owned By Institutions | 13.91 % | ||||
| Number Of Shares Shorted | 5.56 M | ||||
| Price To Earning | (7.60) X | ||||
| Price To Book | 8.56 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.